Bioregenx (BRGX) Equity Average (2022 - 2026)

Bioregenx has reported Equity Average for 5 years, with the latest figure at -$4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 30.73% year-over-year to -$4.5 million; the trailing twelve-month figure through Mar 2026 stood at -$4.5 million (down 30.73% YoY), and the FY2025 full-year result was -$4.0 million, down 45.24% from the prior year.
• Equity Average for Q1 2026 stood at -$4.5 million, down from -$4.1 million in the prior quarter.
• The five-year high for Equity Average was $14.7 million in Q2 2024, with the low at -$4.5 million in Q1 2026.
• Average Equity Average over 5 years is $522129.1, with a median of -$2.4 million recorded in 2023.
• Year-over-year, Equity Average plunged 2560.67% in 2023 and surged 686.61% in 2024.
• Tracing BRGX's Equity Average over 5 years: stood at -$1.4 million in 2022, then sank by 78.76% to -$2.4 million in 2023, then surged by 309.09% to $5.1 million in 2024, then tumbled by 180.38% to -$4.1 million in 2025, then fell by 10.83% to -$4.5 million in 2026.
• The last three Equity Average figures came in at -$4.5 million (Q1 2026), -$4.1 million (Q4 2025), and -$3.7 million (Q3 2025), per Business Quant data.

Peer Comparison